Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen

Further results from NIAID-sponsored ACTT-2 Trial Presented Today INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) are sharing additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical